Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Abstract 1185: Novel association of an autoimmune-related axis and anti-CTLA-4-based toxicities in adjuvant immunotherapy-treated melanoma patients

Kelsey R. Monson, Robert Ferguson, Joanna Handzlik, Jiahan Xiong, Sasha Dagayev, Leah Morales, Vylyny Chat, Anabelle Bunis, Chaitra Sreenivasaiah, Sonia Dolfi, Daniel Tenney, Iman Osman, Jeffrey Weber, Tomas Kirchhoff

Cancer Res (2024) 84 (6_Supplement): 1185.

https://doi.org/10.1158/1538-7445.AM2024-1185

Published: 22 March 2024

View article titled, Abstract 1185: Novel association of an autoimmune-related axis and anti-CTLA-4-based toxicities in adjuvant immunotherapy-treated melanoma patients

Journal Articles

Abstract PO-007: The Class I/IV HDAC Inhibitor Mocetinostat Augments Anti-Tumor Immune Responses in Melanoma Patients

David M. Woods, Andressa S. Laino, Melinda Vassallo, Jeffrey Weber

Cancer Res (2020) 80 (23_Supplement): PO-007.

https://doi.org/10.1158/1538-7445.EPIMETAB20-PO-007

Published: 02 December 2020

View article titled, Abstract PO-007: The Class I/IV HDAC Inhibitor Mocetinostat Augments Anti-Tumor Immune Responses in Melanoma Patients

Journal Articles

Abstract CT120: A randomized, open-label, open-platform, Phase II study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (PLATforM)

Caroline Robert, Reinhard Dummer, Ana Arance, Antoni Ribas, Jeffrey Weber, Georgina V. Long, John Haanen, Paul Nathan, Paolo A. Ascierto, Eduard Gasal, Anthony D'Amelio, Severine Bettinger, Aislyn D. Boran, Dirk Schadendorf

Cancer Res (2019) 79 (13_Supplement): CT120.

https://doi.org/10.1158/1538-7445.AM2019-CT120

Published: 01 July 2019

View article titled, Abstract CT120: A randomized, open-label, open-platform, Phase II study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (PLATforM)

Journal Articles

Abstract 3236: T-cell intrinsic mechanisms of resistance to PD-1 checkpoint blockade

Duane Moogk, Lin Wang, Kaitao Li, Zhou Yuan, Jeffrey Weber, Iman Osman, Cheng Zhu, Michelle Krogsgaard

Cancer Res (2019) 79 (13_Supplement): 3236.

https://doi.org/10.1158/1538-7445.AM2019-3236

Published: 01 July 2019

View article titled, Abstract 3236: T-cell intrinsic mechanisms of resistance to PD-1 checkpoint blockade

Journal Articles

Abstract 4055: Enhancing anti-PD-1 immune blockade in melanoma through selective inhibition of histone deacetylase 6

Tessa Knox, Eva Sahakian, Jayakumar Nair, Jennifer Kim, Debarati Banik, Melissa Hadley, John Powers, Fengdong Cheng, Sida Shen, Javier Pinilla, Jeffrey Weber, Alan Kozikowski, Eduardo Sotomayor, Alejandro Villagra

Cancer Res (2017) 77 (13_Supplement): 4055.

https://doi.org/10.1158/1538-7445.AM2017-4055

Published: 01 July 2017

View article titled, Abstract 4055: Enhancing anti-PD-1 immune blockade in melanoma through selective inhibition of histone deacetylase 6

Journal Articles

Abstract 638: Epigenetic reprograming of immune cells through selective inhibition of HDAC6 reduces suppressive phenotypes and augments anti-tumor properties of T-cells

Andressa L. Sodre, David M. Woods, Amod Sarnaik, Brian C. Betts, Steven Quayle, Simon Jones, Jeffrey Weber

Cancer Res (2017) 77 (13_Supplement): 638.

https://doi.org/10.1158/1538-7445.AM2017-638

Published: 01 July 2017

View article titled, Abstract 638: Epigenetic reprograming of immune cells through selective inhibition of HDAC6 reduces suppressive phenotypes and augments anti-tumor properties of T-cells

Journal Articles

Abstract 4976: Ricolinostat, a selective HDAC6 inhibitor with immunomodulatory properties, has significant antimelanoma activity in vitro and in vivo

Fengdong Cheng, Sodre Andressa, Jie Chen, Alejandro Villagra, David Woods, Jeffrey Weber, Steven Quayle, Jones Simon, Eduardo Sotomayor

Cancer Res (2017) 77 (13_Supplement): 4976.

https://doi.org/10.1158/1538-7445.AM2017-4976

Published: 01 July 2017

View article titled, Abstract 4976: Ricolinostat, a selective HDAC6 inhibitor with immunomodulatory properties, has significant antimelanoma activity in vitro and in vivo

Journal Articles

Abstract 2331: HDAC6, new role as master regulator of PD-L1 and immune-related pathways

Tessa Knox, Maritza Lienlaf, Patricio Perez, Mibel Pabon, Calvin Lee, Fengdong Cheng, Eva Sahakian, John Powers, Susan Deng, Smalley Keiran, Alan Kozikowski, Javier Pinilla, Amod Sarnaik, Ed Seto, Jeffrey Weber, Eduardo Sotomayor, Alejandro Villagra

Cancer Res (2016) 76 (14_Supplement): 2331.

https://doi.org/10.1158/1538-7445.AM2016-2331

Published: 15 July 2016

View article titled, Abstract 2331: HDAC6, new role as master regulator of PD-L1 and immune-related pathways

Journal Articles

Abstract CT133: Association of programmed death-ligand 1 (PD-L1) and 2 (PD-L2) expression with nivolumab (NIVO) efficacy in advanced melanoma (MEL)

Scott J. Rodig, Evisa Gjini, Kaushal Desai, Chelsea Jin, Christine Horak, Mary Ruisi, Jeffrey Weber, Gordon J. Freeman, F. Stephen Hodi

Cancer Res (2016) 76 (14_Supplement): CT133.

https://doi.org/10.1158/1538-7445.AM2016-CT133

Published: 15 July 2016

View article titled, Abstract CT133: Association of programmed death-ligand 1 (PD-L1) and 2 (PD-L2) expression with nivolumab (NIVO) efficacy in advanced melanoma (MEL)

Journal Articles

Abstract 4891: A mass spectrometry-based serum test to predict outcome of treatment with nivolumab: Analysis of samples taken during therapy

Jeffrey Weber, Heinrich Roder, Senait Asmellash, Krista Meyer, Kevin Sayers, Arni Steingrimsson, Joanna Roder

Cancer Res (2016) 76 (14_Supplement): 4891.

https://doi.org/10.1158/1538-7445.AM2016-4891

Published: 15 July 2016

View article titled, Abstract 4891: A mass spectrometry-based serum test to predict outcome of treatment with nivolumab: Analysis of samples taken during therapy

Journal Articles

Abstract 257: Class I HDAC inhibition upregulates PD-1 ligands in melanoma and increases the efficacy of PD-1 blockade

David M. Woods, Andressa L. Sodre, Amod Sarnaik, Eduardo M. Sotomayor, Jeffrey Weber

Cancer Res (2015) 75 (15_Supplement): 257.

https://doi.org/10.1158/1538-7445.AM2015-257

Published: 01 August 2015

View article titled, Abstract 257: Class I HDAC inhibition upregulates PD-1 ligands in melanoma and increases the efficacy of PD-1 blockade

Journal Articles

Abstract 1338: Novel implications of histone deacetylase 6 selective inhibition in melanoma T-cell immunotherapy

Andressa Sodre Laino, David M. Woods, Amod Sarnaik, Esteban Celis, Jeffrey Weber, Eduardo M. Sotomayor

Cancer Res (2015) 75 (15_Supplement): 1338.

https://doi.org/10.1158/1538-7445.AM2015-1338

Published: 01 August 2015

View article titled, Abstract 1338: Novel implications of histone deacetylase 6 selective inhibition in melanoma T-cell immunotherapy

Journal Articles

Abstract B23: Autoimmune hypophysitis is a marker of favorable outcome during treatment of melanoma with ipilimumab

Jennifer M. Eatrides, Jeffrey Weber, Kathleen Egan, Marjorie Acierno, Michael Schell, Howard Lillienfeld, Ben Creelan

Cancer Res (2015) 75 (14_Supplement): B23.

https://doi.org/10.1158/1538-7445.MEL2014-B23

Published: 16 July 2015

View article titled, Abstract B23: Autoimmune hypophysitis is a marker of favorable outcome during treatment of melanoma with ipilimumab

Journal Articles

Autophagy Induced by Conventional Chemotherapy Mediates Tumor Cell Sensitivity to Immunotherapy

Rupal Ramakrishnan, Chun Huang, Hyun-Il Cho, Mark Lloyd, Joseph Johnson, Xiubao Ren, Soner Altiok, Daniel Sullivan, Jeffrey Weber, Esteban Celis, Dmitry I. Gabrilovich

Cancer Res (2012) 72 (21): 5483–5493.

https://doi.org/10.1158/0008-5472.CAN-12-2236

Published: 31 October 2012

View article titled, Autophagy Induced by Conventional Chemotherapy Mediates Tumor Cell Sensitivity to Immunotherapy

Includes: Supplementary data

Journal Articles

Abstract #1931: Th-17 inducibility predicts freedom from relapse after CTLA-4 blockade for the treatment of advanced melanoma

Amod Sarnaik, Michael Yellin, Daohai Yu, Weiwei Zhu, Jeffrey Weber

Cancer Res (2009) 69 (9_Supplement): 1931.

Published: 01 May 2009

View article titled, Abstract #1931: Th-17 inducibility predicts freedom from relapse after CTLA-4 blockade for the treatment of advanced melanoma

Journal Articles

Abstract #724: A phase 1 clinical trial of immune response and safety of an active immunotherapy regimen co-targeting PRAME and PSMA antigens in subjects with advanced solid malignancies

Mihail Obrocea, Nicholas Vogelzang, Lee Cranmer, Marc Ernstoff, Jeffrey Weber, John Marshall, Zhiong Qiu, Darlene Rosario, Adrian Bot

Cancer Res (2009) 69 (9_Supplement): 724.

Published: 01 May 2009

View article titled, Abstract #724: A phase 1 clinical trial of immune response and safety of an active immunotherapy regimen co-targeting PRAME and PSMA antigens in subjects with advanced solid malignancies

Journal Articles

Microarray Analysis Reveals Differences in Gene Expression of Circulating CD8+ T Cells in Melanoma Patients and Healthy Donors

Tong Xu, Chen-Tsen Shu, Elizabeth Purdom, Demi Dang, Diane Ilsley, Yaqian Guo, Jeffrey Weber, Susan P. Holmes, Peter P. Lee

Cancer Res (2004) 64 (10): 3661–3667.

https://doi.org/10.1158/0008-5472.CAN-03-3396

Published: 17 May 2004

View article titled, Microarray Analysis Reveals Differences in Gene Expression of Circulating CD8+ T Cells in Melanoma Patients and Healthy Donors

NARROW

Abstract 1185: Novel association of an autoimmune-related axis and anti-CTLA-4-based toxicities in adjuvant immunotherapy-treated melanoma patients

Abstract PO-007: The Class I/IV HDAC Inhibitor Mocetinostat Augments Anti-Tumor Immune Responses in Melanoma Patients

Abstract CT120: A randomized, open-label, open-platform, Phase II study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (PLATforM)

Abstract 3236: T-cell intrinsic mechanisms of resistance to PD-1 checkpoint blockade

Abstract 4055: Enhancing anti-PD-1 immune blockade in melanoma through selective inhibition of histone deacetylase 6

Abstract 638: Epigenetic reprograming of immune cells through selective inhibition of HDAC6 reduces suppressive phenotypes and augments anti-tumor properties of T-cells

Abstract 4976: Ricolinostat, a selective HDAC6 inhibitor with immunomodulatory properties, has significant antimelanoma activity in vitro and in vivo

Abstract 2331: HDAC6, new role as master regulator of PD-L1 and immune-related pathways

Abstract CT133: Association of programmed death-ligand 1 (PD-L1) and 2 (PD-L2) expression with nivolumab (NIVO) efficacy in advanced melanoma (MEL)

Abstract 4891: A mass spectrometry-based serum test to predict outcome of treatment with nivolumab: Analysis of samples taken during therapy

Abstract 257: Class I HDAC inhibition upregulates PD-1 ligands in melanoma and increases the efficacy of PD-1 blockade

Abstract 1338: Novel implications of histone deacetylase 6 selective inhibition in melanoma T-cell immunotherapy

Abstract B23: Autoimmune hypophysitis is a marker of favorable outcome during treatment of melanoma with ipilimumab

Autophagy Induced by Conventional Chemotherapy Mediates Tumor Cell Sensitivity to Immunotherapy

Abstract #1931: Th-17 inducibility predicts freedom from relapse after CTLA-4 blockade for the treatment of advanced melanoma

Abstract #724: A phase 1 clinical trial of immune response and safety of an active immunotherapy regimen co-targeting PRAME and PSMA antigens in subjects with advanced solid malignancies

Microarray Analysis Reveals Differences in Gene Expression of Circulating CD8+ T Cells in Melanoma Patients and Healthy Donors

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only